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Immunologic Investigations of T-Cell Regulation
of Human IgE Antibody Secretion
and Allergic Responses
David M. Essayan,* Guha Krishnaswamy,† and Shau-Ku Huang*,1
*Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland
21224; and †Department of Medicine, East Tennessee State University, Johnson City, Tennessee 37614-0622

The pathophysiology of allergic disease is multifactorial,
involving an intricate network of interactions among cells,
mediators, and cytokines. Substantial progress has been
made in defining the role of antigen-specific T cells and cytokines in the regulation of immunoglobulin E (IgE) synthesis
and the atopic diseases. The development of antigen-specific
T-cell lines and clones has facilitated efforts to characterize
human T-cell subsets and their cytokine repertoires. Molecular methods currently available include techniques for the
quantitative analysis of cytokine gene expression and secretion from activated T cells ex vivo as well as in tissues. The
availability of these newly developed techniques has become
essential to the investigation of the pharmacologic regulation
of T cells and cytokines both in vitro and in vivo. Future
investigations will contribute to our understanding of the differential regulation of T-cell subsets and their relationships
to allergic diseases, ultimately leading to a better understanding of the molecular pathogenesis of allergic diseases
and the design of more effective therapeutic interventions.
q 1997 Academic Press

A mature CD4/ T cell, through its clonally derived
T-cell receptor (TcR), recognizes a peptide fragment
1
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Bayview Circle, Baltimore, MD 21224-6801. Fax: (410) 550-2090.

of an antigen (Ag) only in the context of a membranebound class II molecule (in humans, HLA-DR, DQ,
or DP) on the antigen-presenting cell (APC; such as
macrophage/dendritic cells and B cells) (for review
of MHC-restricted recognition of allergens, see Ref.
1). This Ag-specific, MHC-restricted event allows for
the induction of the effector functions of T-cell help
and the generation of cytokines. Based on the profile
of cytokines, two functional subsets of T cells have
been described (2): Type 1 T cells (Th1) express IL2 and IFN-g, whereas type 2 T cells (Th2) express
interleukin 4 (IL-4), IL-5, IL-6, and IL-10. In humans, such dichotomy has been observed from cytokine profiling analyses of Ag-specific T-cell clones of
atopic patients (3–6). The molecular basis for and
in vivo importance of these T-cell subsets are not
clearly understood. It has been suggested that cytokines (IL-4, IFNg, and IL-10) play a role in the functional differentiation of T cells; there is reciprocal
regulation of Th1 and Th2 cells by their cytokine
products (7).
Our current understanding of the regulation of
IgE synthesis has been primarily derived from in
vitro experiments, together with functional studies
of recombinant cytokines. Several studies in humans
have indicated that the regulation of IgE is controlled by the reciprocal activity of IL-4 and IFN-g
(8) and requires direct T cell–B cell interactions
with both MHC-restricted and non-MHC-restricted
events (for example, CD-40–gp39 interactions; Ref.
9). Using an allergen challenge model, the presence
69
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of infiltrating T cells and the expression of Th2 cytokines at sites of inflammation have been well documented (10–12). An important implication of these
studies is that in atopic subjects, allergen induces
activation and/or proliferation of cells having the
Th2 cytokine profile, and the expression of Th2 cytokines is critical in the induction of IgE synthesis and
the initiation of allergic responses. The information
gained from these studies has been the basis for designing therapeutic strategies for the modulation of
human T-cell activation and cytokine responses by
a variety of immunopharmacologic agents. In addition, T cells may play a general role in the regulation
of specific immune responses; this is suggested by
the importance of T cells as targets in allergen immunotherapy (13, 14).
The role of T cells and cytokines in the regulation
of IgE synthesis and allergic diseases has been the
subject of several recent reviews (15, 16), to which
the reader is referred for more detailed information and discussion. The present review will focus
on recent developments concerning the immunologic methods and current immunomodulatory approaches used in the study of Ag-specific T-cell responses and their relationships to atopic diseases.

ANTIGEN-SPECIFIC T-CELL POPULATIONS
Antigen-specific T-cell activation involves an initial cognate cellular interaction and subsequent molecular signals selectively transmitted through a
complex series of intracellular phosphorylation/dephosphorylation events. These molecular signals
culminate in the induction of specific gene transcription and translation. While mitogen-driven activation can result in both proliferation and cytokine
generation, much of the specificity of antigen-driven
stimulation is not reproduced by this method (17).
For this reason, we and others have focused considerable effort on the establishment of antigen-driven
systems for the study of T-cell biology and cytokine
pharmacology. While the stimulation of peripheral
blood mononuclear cells (PBMCs) with antigen may
provide relevant ex vivo data, an understanding of
differential functional properties of T-cell subsets
can be achieved only with the use of antigen-specific,
phenotypically characterized T-cell clones.
Antigen-specific human T-cell lines are generated
from the PBMCs of study subjects by periodic stimu-
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lation with antigen in the presence of APCs and Tcell growth factors, such as IL-2 (18). Antigen-specific T-cell clones are generated from these lines by
the limiting dilution technique (usually at 0.3 cell
per well), which in principle follows statistics of the
Poisson distribution. Autologous irradiated PBMCs
or Epstein–Barr virus-transformed B cells are used
as APCs for periodic restimulation and expansion of
the clonal cell populations. Subcloning and analysis
of TcR Vb gene usage are used to confirm monoclonality. The antigen specificity is confirmed by unresponsiveness of the T cells to an irrelevant antigen
(5, 6). The availability of stable, phenotypically characterized, antigen-driven T-cell clones has provided
an excellent tool for the study of T-cell clonal diversity, proinflammatory cytokine production, phenotypic heterogeneity to a single allergen, and the differential pharmacologic regulation of the T-cell
subsets.

ANALYSIS OF CYTOKINE
GENE EXPRESSION
Transcription and secretion of cytokines are dependent on the activation of resting T cells. Several
techniques have been used to quantitate cytokine
gene expression from activated T cells ex vivo or in
situ from foci of inflammation. These include RNase
protection assays, in situ hybridization, Northern
blotting, and the reverse transcription–polymerase
chain reaction (RT-PCR; Ref. 19). Of these techniques, neither Northern blotting nor in situ hybridization provides a quantitative assessment of cytokine mRNA; moreover, in situ hybridization requires
substantial expertise to achieve reproducible results. Two of these techniques, RT-PCR and in situ
hybridization, have been useful in the study of allergic diseases.
Qualitative and Quantitative RT-PCR
The ability to detect and quantitate multiple cytokine mRNAs from small numbers of target cells
makes RT-PCR technology an attractive and powerful tool to assess gene expression (19, 20). In this
technique, RNA is extracted from tissues or cells and
first-strand cDNA synthesized from an aliquot of
RNA (usually 1 mg). Aliquots of cDNA are then subjected to PCR in the presence of cytokine-specific
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primers in an automated thermocycler. The products
of amplification are analyzed by electrophoresis in
agarose gels containing ethidium bromide. The specificity of the amplification is assessed by any or all
of the following methods: the expected sizes of amplified fragments, Southern blotting using internal sequence probes, restriction enzyme digestion, or direct sequencing. This simple methodology provides a
qualitative assessment of cytokine gene expression.
To quantitate the level of cytokine gene expression, modified RT-PCR-based techniques have been
developed. Early methods provided relative quantitation (also referred to as semiquantitative RT-PCR)
of cytokine transcripts by comparing the amounts of
the amplified products of the target template and
a constitutively expressed gene, such as b-actin or
HPRT. Using either radioactive incorporation or
densitometry measurements of the amplified products, the ratio of target gene product and constitutive gene product was calculated and compared between different test samples. Although informative,
this method has inherent shortcomings. Optimal
PCR reactions are dependent on various parameters,
including primer specificity and stability, the concentrations of magnesium and DNA polymerase, cycling profiles, and the number of amplification cycles. These factors account for much of the
variability seen in amplification specificity and efficiency.
The more recent development of ‘‘quantitative,
competitive RT-PCR (QC-PCR)’’ (22) has sought to
minimize some of these problems. In QC-PCR, an
exogenous RNA standard [referred to as the internal
standard (IS)], which is created as an allelic size
variant of the gene of interest (Refs. 11, 21–23), is
amplified in the presence of the same primer set
in the same tube with the target RNA. Thus, the
amplification of both the IS and the target RNA templates is affected equally by variables during RTPCR. The difference in fragment sizes of the IS and
target mRNA allows the two amplified products to
be distinguished on agarose gel. The amount of unknown target mRNA can be extrapolated from the
density or radioactivity ratios of varying dilutions of
the target product amplified with a known concentration of IS. A significant improvement of this technique involves the use of ‘‘polycompetitors’’ to allow
quantitation of multiple target genes with the same
internal standard (24). Finally, a modification
wherein the amplified DNA is captured covalently
onto microtiter plates and quantitated by oligonucle-
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otide hybridization and enzyme-linked immunosorbent assay has recently been described (25).
We have used QC-PCR to study cytokine gene expression in T cells from peripheral blood and bronchoalveolar lavage samples of subjects with airway
inflammation following allergen challenge (11, 21–
23). We demonstrated enhanced expression of
mRNA for the Th2-cytokine, IL-5, in the mononuclear population of asthmatic lung lavage samples.
We have also used semiquantitative RT-PCR to analyze the modulation of cytokine transcripts in
PBMCs and to study the expression of cytokine transcripts in buccal epithelium, human mast cells, and
endothelial cells (26–28). Thus, analysis of cytokine
mRNA from small numbers of a variety of cultured
cells is possible using PCR-based techniques. Figure
1 shows an example of QC-PCR technique.
In Situ hybridization
An additional tool useful in the analysis of cytokine gene expression is in situ hybridization. In this
technique, cytokine mRNAs can be identified within
the cells of tissue sections. When combined with immunocytochemistry, it is a powerful tool to identify
the cell sources of the cytokine mRNAs. The methodology involves fixing target tissue to glass slides,
incubating with hybridization buffer containing the
radiolabelled probe of interest (or the probe in a
‘‘sense’’ direction as a negative control), and visualization by autoradiography (29). Using this technique, Robinson et al. demonstrated an increased
expression of mRNAs for IL-2, IL-4, IL-5, and GMCSF in the lung lavages of asthmatic patients. They
also demonstrated that in patients with asthma, IL4 and IL-5 were expressed predominantly by the T
cells (10). Using in situ hybridization, Varney et al.
showed that successful grass pollen immunotherapy
was associated with an increase in the number of
IL-2- and IFN-g-stained cells (30). Finally, Durham
et al. demonstrated that the number of IFN-gstained cells increased in the nasal biopsies of patients treated with grass pollen immunotherapy
(31). Thus, in situ hybridization has provided significant insights into the pathogenesis of allergic inflammation.

ANALYSIS OF CYTOKINE PROTEIN
SECRETION
While the assessment of proinflammatory cytokine gene expression from T cells may provide a pre-
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cise and highly sensitive indication of cellular activation states, transcriptional and posttranscriptional
regulatory events may influence the ultimate outcome of cellular activation. For this reason, gene expression data are often combined with direct or indirect measurements of cytokine protein generation.
Currently, the three primary methods used for cytokine protein measurement are bioassays, enzymelinked immunosorbent assays (ELISA), and flow cytometry with intracellular cytokine staining.

interest but present in the sample undergoing analysis. While these assays often require considerable
maintenance, they provide an inexpensive and
highly sensitive measurement of cytokine production. For example, Gleich and colleagues have developed an eosinophil survival assay for the measurement of IL-5 with a sensitivity of 22 fmol and a
usable range of two orders of magnitude (32). With
rare exceptions, these assays have been supplanted
by other techniques.

Bioassays
Bioassays for the assessment of cytokine production have been established in many laboratories for
many cytokines. Bioassays detect the biological activity of the cytokine through a growth-promoting
effect on a dependent cell line; nonfunctional cytokine will not be detected by this method. However,
bioassays may be subject to interference by additional growth factors not related to the cytokine of

Enzyme-Linked Immunosorbent Assay
ELISA assays for the detection of many cytokines
and other molecular targets are available commercially. These assays boast sensitivities as low as 0.1
pg. They offer the advantages of high precision,
species specificity, negligible cross-reactivity with
closely related molecular structures, and a high resistance to interference by serum proteins or other
incidental factors. Using commercially available

FIG. 1. Quantitative analysis of interleukin 5 mRNA expression. (a) Total cellular RNA from antigen-stimulated PBMCs was
reverse-transcribed with an oligo(dT) primer and subjected to PCR. (Top) Constitutive expression of b-actin at each of four time
points. (Bottom) The increasing competition of native IL-5 transcript (293-bp fragment) with a constant amount of IS (387-bp
fragment). (b) A fixed amount of total cellular RNA from the 6- and 9-h time points is subjected to QC-PCR with varying amounts
of the IS competitor, as shown. (c) Quantitation of the individual bands in (b) (by radioactive incorporation or densitometry measurements) is depicted graphically. The concentration of IL-5 in the test sample is determined by the amount of IS at the IS/test sample
ratio of 1. In this experiment, low levels of IL-5 mRNA are present at 3 h and increase at 6 h (0.1 pg/200 ng RNA) and 9 h (0.3 pg/
200 ng total RNA). Experimental variability is typically less than 5% (22).
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ELISA kits for various cytokines, we have conducted
a study to characterize the cytokine profiles of a
short ragweed allergen (Amb a 1)-specific T-cell
clones from two allergic subjects and one nonallergic
subject (6). The clones studied were uniformly CD3/
CD4/ CD80 by flow cytometry. We demonstrated
that while the clones from the atopic subjects were
predominantly Th0 with lesser numbers of Th1 and
Th2 clones, clones from the nonatopic subject were
uniformly of the Th1 phenotype. Detailed analysis
of cytokine profiles from these clones allowed us to
show uniformly high levels of IL-13 (ú4 ng/ml/2 1
105 cells) production, regardless of cellular phenotype (Fig. 2). These levels did not correlate with levels of IL-4 production and implicate IL-13 directly
in the generation of chronic allergic inflammation.
While the majority of ELISA assays employ a standard ‘‘sandwich’’ method for the measurement of free
ligand, a number of modified ELISA assays have
recently been developed. One such modification uses
a biotinylated cytokine competitor to detect both free
and bound fractions of the target cytokine (33, 34).
Another assay allows the culture of cytokine-producing cells directly in the presence of the primary anticytokine antibody. This enables cumulative detec-
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tion of secreted cytokine, obviating the influence of
autocrine consumption (35, 36). Finally, a variation
on the sandwich ELISA methodology using a biotinylated oligonucleotide with subsequent PCR as the
detection system has been employed to improve sensitivity to the 10 fg range (37).
Flow Cytometry with Intracellular Cytokine Staining
The most recent development in the area of cytokine protein detection has been the development of
intracellular cytokine staining of fixed and permeabilized cells with labeled monoclonal antibodies
and subsequent detection by flow cytometry. Such
methods usually employ an agent such as momensin
to inhibit secretion of cytokine protein, enhancing
intracellular accumulation and facilitating staining.
This methodology offers the advantages of detection
of multiple cytokines simultaneously on a single-cell
level and the characterization of cytokine production
profiles of cell populations. Prussin and colleagues
have used flow cytometric techniques to identify distinct Th0, Th1, and Th2 subsets in human CD4/
CD270 lymphocytes and have demonstrated the utility of this technique in studying increased IL-5 production characteristic of hypereosinophilic states
(38, 39). However, reliable cytokine detection has
only been achieved with the use of mitogenic stimuli;
the feasibility of this assay in detection of cytokine
production in antigen-driven T-cell populations remains to be determined.

PHARMACOLOGIC MODULATION OF T-CELL
RESPONSES

FIG. 2. IL-4 and IL-13 secretion in Amb a 1-specific T cells.
Amb a 1-specific T-cell clones were derived from an atopic subject
(MT) and a nonatopic subject (SH). All T-cell clones (eight from
subject MT, solid squares; eight from subject SH, open squares)
were stimulated with Amb a 1 (10 mg/ml) in the presence of
autologous APCs. Culture supernatants were collected 24 h after
stimulation; IL-4 and IL-13 from these supernatants were quantitated by ELISA.
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It is clear that significant progress has been made
in the development of cellular and molecular tools
for characterizing antigen-induced activation of T
cells; these new developments have facilitated pharmacologic studies of T cell and cytokine responses
in disease states. For example, the generation of proinflammatory cytokines may be downregulated by a
variety of therapeutic agents for the atopic diseases.
Studies from our laboratory and others have documented the efficacy of corticosteroids, nonselective
and selective phosphodiesterase (PDE) inhibitors,
and peptide immunotherapy in the downregulation
of Th2 cytokines.
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Glucocorticoids
Glucocorticoids are potent antiinflammatory
agents that affect a variety of immune cells. In lymphocytes, glucocorticoids bind a specific cytoplasmic
receptor; this complex translocates to the nucleus,
where it is felt to induce the transcription of a number of regulatory genes including the IkBa gene. The
product of this gene prevents nuclear translocation
of NF-kB, a trans-acting regulatory protein for proinflammatory cytokines including IL-4. Thus, corticosteroids may downregulate allergic inflammatory responses (40).
We have used antigen-driven PBMCs and antigenspecific T-cell clones of the Th0, Th1, and Th2 subtypes to conduct a detailed analysis of differential
kinetics and efficacy of corticosteroids (41). Our results demonstrated a strong dose-dependent downregulation of PBMC responses to a variety of antigens (IC50 for dexamethasone Å 3 nM); moreover,
significant downregulation of antigen-driven responses could be achieved even with the addition of
dexamethasone 36 h after initial antigen stimulation. Analysis of cytokine protein production from
ragweed (Amb a 1)-stimulated Th1 and Th2 clones
revealed dose-dependent downregulation of cytokines from both T-cell subsets with a panel of corticosteroids (dexamethasone, budesonide, and hydrocortisone). Of note, IFN-g production showed a
significantly greater sensitivity to inhibition with
1007 M budesonide and 1006 M hydrocortisone (P Å
0.02 and 0.03, respectively) than did IL-4 production.
Differences in IFN-g and IL-4 production in cultures
with lower doses of corticosteroids were not significant (P uniformly ú 0.1) (Fig. 3a). IL-13 secretion
showed similar, dose-dependent inhibition from either Th1 or Th2 clones with any of the three corticosteroids; no significant differences between the phenotypes were observed (P uniformly ú 0.3) (Fig. 3b).
Thus, the clinical efficacy of corticosteroids may be
due to their downregulatory effects on T-cell-derived
proinflammatory cytokine production.
Phosphodiesterase Inhibitors
Phosphodiesterase (PDE) isozymes catalyze the
degradation of intracellular cyclic nucleotides; their
inhibition results in the upregulation of steady-state
cyclic nucleotide levels with activation of specific
protein kinase isoforms. Elevations of cAMP have
been shown to downregulate immunologic responses
to both mitogenic and antigenic stimuli. Phosphodi-
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esterase enzymes may be classified into seven distinct families based on substrate specificity, inhibitor sensitivity, and sequence homology; PDE3,
PDE4, and PDE7 have been shown to specifically
regulate cAMP levels (42). We have investigated the
efficacy of selective inhibitors of PDE3 and PDE4 in
antigen-specific T-cell responses. In PBMCs, inhibitors of the PDE4 isozymes cause dose-dependent
downregulation of T-cell proliferative responses and
gene expression of proinflammatory cytokines. The
low number of antigen-specific target cells in these
assays precludes adequate analysis of cytokine secretion (43, 44). However, using phenotypically characterized T-cell clones, we have demonstrated dosedependent downregulation of IL-4 and IL-13 protein
production by PDE4 inhibitors (Fig. 4); PDE3 inhibitors, while capable of elevating intracellular cAMP,
are ineffective in modulating cytokine protein production, perhaps due to compartmentalization of cyclic nucleotide-mediated signals (45). Demonstration
of clinical efficacy for these agents awaits the results
of ongoing phase 2 trials.
Peptide Immunotherapy
Despite nearly a century of use and proven efficacy
in the treatment of allergic rhinitis and allergic
asthma, the precise mechanism of immunotherapy
remains unclear. A number of alterations in immune
function have been documented during immunotherapy, including a decline in antigen-specific IgE levels, an increase in antigen-specific IgG levels, and a
diminution of antigen-specific lymphocyte responsiveness (46). Recently, using mitogen-stimulated
short-term T-cell lines, a number of investigators
have provided evidence to suggest a phenotypic shift
in responder T cells from a Th2 population to a Th1
population during immunotherapy. These investigators have advanced the hypothesis that this shift
accounts for the clinical benefit seen with immunotherapy (13, 14). We have recently completed an ex
vivo study of antigen-specific T-cell responses from
participants in a randomized, double-blind, placebocontrolled study of two different doses of a peptide
immunotherapy product (47). In this study, subjects
were immunized with a combination of two recombinant peptides containing the major epitopes of Fel
d 1, the major allergen of cat dander extract. Shortterm T-cell lines were derived from each subject before and after immunotherapy, using cat dander extract, the recombinant peptides, or tetanus toxoid
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(an irrelevant antigen). While antigen-specific T-cell
proliferative responses were unchanged by immunotherapy, peptide-induced IL-4 secretion was downregulated by immunotherapy. Moreover, this downregulation was greater in the high-dose treatment
cohort than the low-dose treatment cohort; this effect correlated closely with clinical outcomes in the
treatment groups. While an inverse trend for IFNg production was noted, this did not reach statistical
significance. Finally, significant changes in IL-4 and
IFN-g production were not evident in the cell lines
derived with either the more nonspecific cat dander
extract or the irrelevant tetanus toxoid antigen.
These data support the hypothesis of T-cell phenotypic shift as a mechanism for the efficacy of immu-
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notherapy and underscore the high degree of antigen
specificity of this treatment modality.

CONCLUSION
Advances in cellular and molecular methods have
provided essential tools for examining the role of
antigen-specific T cells and cytokines in the regulation of IgE synthesis and the pathogenesis of allergic
diseases. These and other newly developed techniques will be crucial in our effort to define the differential regulatory roles of Th1 and Th2 cells in allergic and immunologic diseases. However, it is

FIG. 3. (a) Modulation of IFN-g (top) and IL-4 (bottom) secretion by corticosteroids. Cytokine protein, measured by ELISA, is shown
for Th1 (top) and Th2 (bottom) clones stimulated in the presence of three concentrations of each of three steroids (Dex, dexamethasone
1007, 1009, and 10010 M; Bud, budesonide 1007, 1009, and 10010 M; HC, hydrocortisone 1006, 1008, and 1009 M). The data are presented
as the percentage of inhibition { SEM relative to stimulated, steroid-free control cultures. (b) Modulation of IL-13 secretion by
corticosteroids. IL-13 protein, measured by ELISA, is shown for Th1 and Th2 clones stimulated under the same culture conditions
indicated in a. The data are presented as the percentage of inhibition { SEM relative to stimulated, steroid-free cultures.
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imperative that the results obtained from studies of
long-term cultured T cells be compared to results
from a more ‘‘physiologic’’ system, such as the mixed
cell population of a disease-targeted organ. An im-

proved understanding of disease pathogenesis and
the contribution of various cell types may be
achieved with quantitative or in situ PCR in combination with immunohistochemistry or ELISA for

FIG. 4. Modulation of IL-4 (top) and IL-13 (bottom) secretion by PDE inhibitors. Cytokine protein, measured by ELISA, is shown
for each of eight T-cell clones under culture conditions without PDE inhibitors (Drug-Free), with rolipram 1005 M (PDE4 inhibitor),
with siguazodan 1005 M (PDE3 inhibitor), or with both. Shaded symbols, Th0; black symbols, Th1; and white symbols, Th2. Mean
values in pg/ml are shown by the horizontal bars.

AID

Methods A 0498

/

6718$$$144

07-31-97 09:39:52

metaas

AP: Methods A

INVESTIGATIONS OF HUMAN T-CELL RESPONSES

cell-associated or secreted proteins; such innovative
approaches will assist in the molecular classification
of various diseases and provide a powerful tool for
monitoring the efficacy of therapeutic interventions.
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